JP7517997B2 - プログラニュリンを含む融合タンパク質 - Google Patents

プログラニュリンを含む融合タンパク質 Download PDF

Info

Publication number
JP7517997B2
JP7517997B2 JP2020570444A JP2020570444A JP7517997B2 JP 7517997 B2 JP7517997 B2 JP 7517997B2 JP 2020570444 A JP2020570444 A JP 2020570444A JP 2020570444 A JP2020570444 A JP 2020570444A JP 7517997 B2 JP7517997 B2 JP 7517997B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
identity
progranulin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527656A5 (https=
JP2021527656A (ja
Inventor
パオロ ギルバート ディ
トッド ピー． ローガン
キャサリン エム． モンロー
アンキタ スリヴァスタヴァ
レンゲリッチ ベティーナ ヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2021527656A publication Critical patent/JP2021527656A/ja
Publication of JP2021527656A5 publication Critical patent/JP2021527656A5/ja
Application granted granted Critical
Publication of JP7517997B2 publication Critical patent/JP7517997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020570444A 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質 Active JP7517997B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US62/686,579 2018-06-18
US201862746338P 2018-10-16 2018-10-16
US62/746,338 2018-10-16
PCT/US2019/037695 WO2019246071A1 (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Publications (3)

Publication Number Publication Date
JP2021527656A JP2021527656A (ja) 2021-10-14
JP2021527656A5 JP2021527656A5 (https=) 2022-06-27
JP7517997B2 true JP7517997B2 (ja) 2024-07-17

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570444A Active JP7517997B2 (ja) 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質

Country Status (17)

Country Link
US (3) US20210284702A1 (https=)
EP (1) EP3807322A1 (https=)
JP (1) JP7517997B2 (https=)
KR (1) KR20210027377A (https=)
CN (1) CN112424233A (https=)
AU (1) AU2019288212B2 (https=)
BR (1) BR112020025306A2 (https=)
CA (1) CA3101202A1 (https=)
CL (1) CL2020003255A1 (https=)
EC (1) ECSP20081591A (https=)
IL (1) IL279510B2 (https=)
MX (1) MX2020012518A (https=)
PE (1) PE20210323A1 (https=)
PH (1) PH12020552189A1 (https=)
SG (1) SG11202011743SA (https=)
TW (1) TWI874321B (https=)
WO (1) WO2019246071A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
AU2016270587B2 (en) * 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2020037150A2 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
JP7624919B2 (ja) * 2018-10-16 2025-01-31 デナリ セラピューティクス インコーポレイテッド プログラニュリン関連障害を処置及びモニタリングするための方法
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) * 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP7817757B2 (ja) * 2020-09-18 2026-02-19 アイユーシーエフ－エイチワイユー（インダストリー－ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ） ＰＴＰｓｉｇｍａ－Ｆｃ融合タンパク質およびそれを含む薬学組成物
KR102666958B1 (ko) * 2020-09-18 2024-05-23 한양대학교 산학협력단 PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물
WO2022082178A2 (en) 2020-10-14 2022-04-21 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
AU2022415476A1 (en) * 2021-12-17 2024-07-04 Denali Therapeutics Inc. Fusion proteins comprising alpha-l-iduronidase enzymes and methods
EP4508206A1 (en) * 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
EP4526344A1 (en) * 2022-05-16 2025-03-26 Denali Therapeutics Inc. Transferrin receptor-binding domains and proteins comprising the same
JP2026501108A (ja) * 2022-12-06 2026-01-14 プロテインキュア インコーポレイテッド ソルチリンの標的化
US20250000992A1 (en) 2023-06-21 2025-01-02 Eli Lilly And Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
WO2018024162A1 (en) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Glp-1 fusion protein comprising mutated immunoglobulin fc portion
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Protein Engineering, Design and Selection，2010年，Vol.23, No.4，PP.289-297

Also Published As

Publication number Publication date
IL279510B2 (en) 2025-11-01
US20230406898A1 (en) 2023-12-21
AU2019288212B2 (en) 2026-04-16
MX2020012518A (es) 2021-02-16
CL2020003255A1 (es) 2021-05-28
IL279510A (en) 2021-01-31
US20210284702A1 (en) 2021-09-16
ECSP20081591A (es) 2021-01-29
BR112020025306A2 (pt) 2021-03-09
PH12020552189A1 (en) 2021-06-28
PE20210323A1 (es) 2021-02-18
IL279510B1 (en) 2025-07-01
TWI874321B (zh) 2025-03-01
EP3807322A1 (en) 2021-04-21
JP2021527656A (ja) 2021-10-14
KR20210027377A (ko) 2021-03-10
AU2019288212A1 (en) 2020-12-03
WO2019246071A1 (en) 2019-12-26
TW202016152A (zh) 2020-05-01
SG11202011743SA (en) 2021-01-28
US20260001925A1 (en) 2026-01-01
CA3101202A1 (en) 2019-12-26
CN112424233A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
JP7517997B2 (ja) プログラニュリンを含む融合タンパク質
US11643446B2 (en) Progranulin variants
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
JP7280241B2 (ja) 操作されたトランスフェリン受容体結合ポリペプチド
JP2025083406A (ja) 操作されたトランスフェリン受容体結合ポリペプチド
WO2020037150A2 (en) Engineered bispecific proteins
WO2021133907A1 (en) Progranulin variants
JP2020508053A (ja) 操作されたポリペプチド
EA049541B1 (ru) Слитые белки, содержащие програнулин
HK40046687A (en) Fusion proteins comprising progranulin
EA049817B1 (ru) Варианты програнулина
HK40079659A (en) Progranulin variants
HK40031685A (en) Fusion proteins comprising enzyme replacement therapy enzymes
HK40018508A (en) Engineered transferrin receptor binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240704

R150 Certificate of patent or registration of utility model

Ref document number: 7517997

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150